Skip to main content
α
中文
Back to research

UnitedHealth (UNH) stock analysis · Nov 2026

Updated regularlyUS stockHealthcare
Written Nov 8 (close at the time $394.15, 11/6)Latest close $339.85 (11/20)Price change since: -13.8%P/E (TTM) 19.4 · Next earnings 2027-01-12

At a glance

The most concerning issue in the current market is: after the short-term correction of United Health (UNH) stock price, whether the technical trend has broken out, and whether its high leverage and changes in earnings quality constitute a substantial challenge to the long-term bull market pattern.

Key research points

  • Price is approaching key support: the closing price at the time of writing of $394.15 has been lower than the middle track of the Bollinger Bands at $398.67, and it has tested the $388.00 support level for two consecutive days, indicating that the short-term momentum has weakened.
  • Bull Indicators Moderating: MACD value fell from 8.40 to 7.79 and RSI fell from 59.46 to 56.18, indicating that the upward momentum is fading.
  • Financial structure under pressure: The debt-to-equity ratio reached 70.43%, and the current ratio was only 0.739, reflecting the company's short-term debt repayment pressure, although free cash flow was as high as $26.501 billion.
  • Earnings quality in doubt: Net profit margin was at a five-year low of 3.53%, operating profit margin fell, while the loss ratio climbed to 86.7%, above the warning line.
  • Challenges to the growth model: The customer surrender rate reached a record high of 21%, the contribution margin of new customers was negative, and the unit economic model deteriorated.
  • The matching between valuation and growth is questionable: Although the forward P/E ratio of 16.93 is lower than the current P/E ratio of 22.50, it does not reflect the decline in profitability and structural risks.

Bull case

  • The long-term trend is still in an upward channel, and the 200-day moving average of $359.62 is significantly lower than the current price, confirming that the overall bull market structure has not changed.
  • Free cash flow continues to be strong, with TTM reaching US$26.501 billion, and the ability to support dividends, repurchases and debt management.
  • The demand for medical services is rigid, the aging trend is irreversible, and the long-term care insurance market has a solid foundation, supporting future income growth.
  • The forward P/E ratio of 16.93 is lower than the industry average, which combined with the PEG ratio of 1.0 shows that valuation and growth are basically matched.
  • As risk aversion in the macro environment heats up, defensive sectors such as insurance stocks may receive capital inflows, forming phased support.

Cautious view

  • The technical picture shows signs of breaking, falling below the $395 psychological mark continuously and testing the $388 support. If it falls, it will open up downside space to below $380.
  • The current ratio is below 1, net debt reaches US$48.486 billion, interest expenses account for 18.7% of net profit, and financial burdens increase.
  • The net profit margin hit a five-year low, the loss ratio continued to rise, and the customer surrender rate hit a new high, reflecting the pressure on product competitiveness and pricing capabilities.
  • Free cash flow growth (4.3%) is lower than revenue growth (5.3%), profits are swallowed up by revenue, and the sustainability of growth is questionable.
  • The company is undergoing a transformation from high-margin traditional business to low-margin medical technology, with diminishing marginal contribution and deteriorating unit economic model.

Risks

  • Financial Risk: The debt-to-equity ratio is high and the current ratio is lower than 1. If interest rates rise further, interest costs will increase significantly.
  • Operation Risk: The loss rate continues to rise, and the customer surrender rate reaches a new high, which may affect the renewal rate and long-term profitability stability.
  • Valuation Risk: Although the forward P/E ratio is low, the rationality of valuation is facing re-evaluation against the background of deteriorating fundamentals.
  • Policy Risk: Changes in U.S. medical insurance policies or tightening of regulations may affect insurance product pricing and information disclosure requirements.
  • Competitive Risk: The potential layout of emerging platforms (such as Apple Health, Amazon Health) may impact the traditional insurance business.

Metrics to watch

  • Changes in loss ratio and surrender rate: If it continues to be higher than 85% and 20%, it will intensify the pressure on profitability, and you need to be wary of further compression of profits.
  • Comparison of free cash flow and net profit growth: If the free cash flow growth rate continues to be lower than the net profit growth rate, it reflects the decline in operating quality.
  • Customer retention rate and renewal rate: As the core indicator to measure product attractiveness, its trend changes directly affect long-term revenue stability.
  • Return on investment and proportion of interest expenses in the quarterly financial report: It can verify the health of the financial structure and capital efficiency.
  • Federal Reserve Interest Rate Policy and Inflation Data: A high interest rate environment is beneficial to the investment side of insurance companies, but it will increase liability costs and policy interest rates, creating a "double kill" effect.

Regularly updated · want it fresher? Sign up for 3 free on-demand reports

US, Hong Kong and China ADR names alike. Understand what happened to a company recently and why — the decision is yours.

This page is research and explanation. It is not directed at any individual's investment decision and is not investment advice. Investing involves risk.

Related: Healthcare

Other research in the same sector and market, to put UNH in context.

Eli Lilly
LLY · Healthcare
Thermo Fisher
TMO · Healthcare
Abbott
ABT · Healthcare
Merck
MRK · Healthcare
Johnson & Johnson
JNJ · Healthcare
Pfizer
PFE · Healthcare
See all 150 stock research pages → · Research hub · Earnings briefs
UnitedHealth (UNH) P/E 19.4 | Stock Analysis 2026: Earnings, Valuation & Risks — AlphaLens